Serial monitoring of genomic alterations in circulating tumor cells of ER‐positive/HER2‐negative advanced breast cancer: feasibility of precision oncology biomarker detection

Nearly all estrogen receptor (ER)‐positive (POS) metastatic breast cancers become refractory to endocrine (ET) and other therapies, leading to lethal disease presumably due to evolving genomic alterations. Timely monitoring of the molecular events associated with response/progression by serial tissu...

Descripción completa

Detalles Bibliográficos
Autores principales: Cani, Andi K., Dolce, Emily M., Darga, Elizabeth P., Hu, Kevin, Liu, Chia‐Jen, Pierce, Jackie, Bradbury, Kieran, Kilgour, Elaine, Aung, Kimberly, Schiavon, Gaia, Carroll, Danielle, Carr, T. Hedley, Klinowska, Teresa, Lindemann, Justin, Marshall, Gayle, Rowlands, Vicky, Harrington, Elizabeth A., Barrett, J. Carl, Sathiyayogan, Nitharsan, Morrow, Christopher, Sero, Valeria, Armstrong, Anne C., Baird, Richard, Hamilton, Erika, Im, Seock‐Ah, Jhaveri, Komal, Patel, Manish R., Dive, Caroline, Tomlins, Scott A., Udager, Aaron M., Hayes, Daniel F., Paoletti, Costanza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120891/
https://www.ncbi.nlm.nih.gov/pubmed/34866317
http://dx.doi.org/10.1002/1878-0261.13150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120891/
https://www.ncbi.nlm.nih.gov/pubmed/34866317
http://dx.doi.org/10.1002/1878-0261.13150

Ejemplares similares